<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 22,
1998 (January 9, 1998)
Commission File No. 0-11772
NU-TECH BIO-MED, INC.
(Exact name of registrant as specified in its charter)
Delaware 25-1411971
(State or other jurisdiction of (IRS Employer Identification No.)
incorporation of organization)
476 Main Street, Suite 3-DFL, Wakefield, Rhode Island 02879
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (401) 789-9995
----------------------------------------
(Former name or former address, if changed since last report.)
Page 1 of 3
<PAGE> 2
ITEM 5. OTHER EVENTS
By letter dated January 6, 1998, received by the Company on January 9,
1998, the Company was advised by the Nasdaq Stock Market that the price for the
Company's Common Stock for the preceding 10 consecutive trading days was such
that the Company's stock failed to maintain a closing bid price of $1.00 or, as
an alternative, a market value of the public float of $1,000,000. However, based
on the closing price for the Company's Common Stock on January 12, 1998, of
$.125, the market value of the Company's public float was approximately
$5,965,538.63. Consequently, the Company believes that it currently complies
with the existing Nasdaq listing requirement and has so advised Nasdaq.
Notwithstanding the foregoing, on February 23, 1998, new Nasdaq listing
and maintenance requirements go into effect. As part of the new requirements,
the alternative to the minimum bid price requirement discussed above will be
eliminated. Although the Company is investigating the feasibility of seeking
shareholder approval for a reverse split of its Common Stock at a yet to be
determined rate which would result in the Company's Common Stock becoming
mathematically in excess of the minimum $1.00 bid price requirement on a
post-split basis, there can be no assurance that such a reverse stock split will
be feasible, that such reverse stock split can be effected in the time required
to avoid delisting, or that such reverse stock split will result in the Company
being in compliance with the new Nasdaq standards.
Page 2 of 3
<PAGE> 3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report on Form 8-K to be signed on its
behalf by the undersigned hereunto duly authorized.
NU-TECH BIO-MED, INC.
By: /s/ J. Marvin Feigenbaum
------------------------
J. Marvin Feigenbaum
Chairman of the Board,
President, Chief Executive
and Chief Financial Officer
Dated: January 21, 1998
Page 3 of 3
